Prostate News and Research

RSS

MRI-guided laser ablation offers way to kill tumors

Physicians at Mayo Clinic's Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.

15 Oct 2010

Robot-assisted brachytherapy for treating prostate cancer

In the first-of-a-kind clinical trial, a robot will be used to place therapeutic radioactive seeds in prostate cancer patients. The National Cancer Institute-supported study, which will enroll 14 patients, has just opened at Thomas Jefferson University Hospital.

15 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Magellan clinical leaders discuss solutions to improve mental illnesses

On the heels of Mental Illness Awareness Week, clinical leaders from Magellan Health Services, Inc., an industry leader in behavioral health care management, are now gathering to discuss a variety of innovative solutions for addressing the unique needs and improving outcomes of individuals with mental illnesses.

14 Oct 2010

IsoRay initiates study of Cesium-131 brachytherapy seeds for NSCLC cancer

IsoRay, Inc. announced today the initiation of a multi-institutional study of Cesium-131 brachytherapy seeds (internal radiation therapy) for use in Non Small Cell Lung Cancers (NSCLC). A number of institutions and physicians will be working to collect scientific data to further the use of Cesium-131 internal radiation therapy in conjunction with surgery for NSCLC.

14 Oct 2010

Humanitas Clinic treats first cancer patient using TrueBeam technology

A 54-year-old head & neck cancer patient has become the first person in Italy to be treated using a revolutionary new linear accelerator that can deliver radiotherapy twice as fast as conventional therapy machines. The Humanitas Clinic in Rozzano-Milan carried out the treatment last week, becoming only the third hospital in Europe to begin clinical treatments using TrueBeam from Varian Medical Systems.

13 Oct 2010

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

13 Oct 2010

First Edition: October 13, 2010

Today's early morning highlights from major news organizations looks at the number of people denied health coverage by major insurers, arguments before the Supreme Court on the right to sue vaccine makers, concerns about the FDA's plans on reviewing medical devices and doctors moving from private practice to hospital work.

13 Oct 2010

Cancer Research UK launches programme to turn genetic revolution into better treatment for cancer patients

Cancer Research UK has launched a multimillion pound programme, alongside the Technology Strategy Board's Innovation Platform, to help turn the genetic revolution into better treatment for cancer patients.

13 Oct 2010

Patients with advanced cancer undergo common non-beneficial cancer screening tests

A sizeable proportion of patients with advanced cancer and a life expectancy of only a few years continue to undergo common cancer screening tests that are unlikely to provide meaningful benefit, according to a study in the October 13 issue of JAMA.

13 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

Threshold announces TH-302 Phase 1/2 clinical trial interim results

Threshold Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1/2 clinical trial in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented at the European Society for Medical Oncology (ESMO) Annual Meeting being held in Milan, Italy.

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Cancer patients getting unnecessary tests: Study

US researchers revealed that many cancer patients with only a few years to live often continue to get routine mammograms or blood tests for prostate cancer even though they are not likely to live long enough to benefit from them. This not only wastes money but also exposes patients to unnecessary worry and distress.

12 Oct 2010

Challenges in provision of high-quality health care at end of life

Health care in the last six months of life has become progressively more expensive for patients with heart failure both among Medicare beneficiaries in the United States and older adults in Canada, with a high rate of hospitalizations in the final six months of life in both countries, according to two reports posted online today that will be published in the February 14 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

Most men with prostate cancer not referred to hospice care early enough

More than half of men dying of prostate cancer use hospice care - a significant increase over the last two decades - but most wait too long to enroll so they can't take full advantage of the palliative care that could make their deaths easier, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center found.

12 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

CTCA in Tulsa purchases BSD-2000 Hyperthermia System

BSD Medical Corporation announced today that the Cancer Treatment Centers of America (CTCA), located in Tulsa, Oklahoma, has purchased a BSD-2000 Hyperthermia System (BSD-2000). CTCA in Tulsa is a state-of-the-art hospital that is totally focused on treating cancer patients and provides the most advanced therapeutic resources in cancer treatment.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010